Clinical Trial Update: FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women [Phase 3]

View source ↗

Summary

A Phase 3 FEM-PrEP trial evaluating Truvada for HIV prevention in women has completed, with results posted in April 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: FHI 360 | Conditions: HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2014-04-16